Follistatin 344 (FS-344, the full-length amino acid isoform of follicle-stimulating hormone 344) is considered a "heavy-duty wrench" in the peptide community-while Sermorelin and Ipamorelin, mentioned earlier, gently push along the physiological axis, FS-344 directly cuts the brakes on muscle growth. It is a naturally occurring glycoprotein in the human body, and 344 is the full-length isoform (after secretion, the signal peptide is cleaved, becoming the circulating FST-315). Recombinant expression is primarily sold in research-grade form.
Core Advantages and Functions
Unique Pathway: Complementary and non-overlapping with IGF-1 LR3 and GH peptides-the latter are like "stepping on the gas," while FS-344 is like "releasing the brakes." It is often used in combination with IGF-1 LR3 or HGH, theoretically resulting in a synergistic effect of muscle gain and loss.
Rumored Experiences: Anonymous blog posts often mention 100-200 mcg/day subcutaneously, short cycles of 10-30 days, with reports of "exploding" in the shoulders, back, and trapezius, a training pump lasting until the second day, and regression to baseline after 4-6 weeks of stopping treatment. However, the other half of the community reports "nothing happened except for two days of swelling at the injection site"-the actual bioavailability and true systemic inhibition in humans remain unclear.
The Double-Edged Sword of Incidental Effects: Typing it to activin can also affect the FSH/LH axis (reproductive endocrine disturbance), making it not purely muscle-selective; this is why FST-315 is considered "more muscle-specific," while 344 is more potent but has more severe hormonal side effects.
Storage Conditions
Unreconstituted lyophilized powder: Store at room temperature, protected from light, and avoid high temperature and humidity.
Reconstituted solution: Must be refrigerated (2-8°C) and used within 28-30 days.
Reconstitution method: Use only bacteriostatic water; do not use physiological saline (may cause precipitation).
Do not freeze; do not shake vigorously (gently vortex to mix).
Keep away from direct light and heat sources.
The solution should be clear and colorless; discard immediately if it changes color or becomes cloudy.
Precautions
Usage and regimen:
Common subcutaneous injection regimens in the community (Note: These regimens are not supported by formal clinical trials and are all extrapolated from gene therapy data):
Loading period: 10 days, 100 micrograms daily
Maintenance period: 100 micrograms every other day thereafter
Total treatment course: Usually 30 days as one cycle, followed by a 4-8 week rest period
Common side effects (relatively mild):
Injection site reaction - Redness, swelling, mild pain; can be relieved by rotating sites
Headache, fatigue - Occurs in a few people, usually transient
Nausea - May occur with high doses
Dizziness/blood pressure fluctuations - Rare, but requires monitoring in patients with hypertension.
Real risks to be wary of (these are not trivial):
1. Rapid muscle growth, but connective tissue not keeping up.
This is the most underestimated risk of Follistatin 344. Tendons and ligaments strengthen much slower than muscles. If your muscles grow rapidly within a few weeks, but your tendons haven't adapted, the risk of strains and tears increases dramatically. Many experienced users combine it with BPC-157 and TB-500 to support connective tissue repair. Avoid heavy, extreme training for the first 2-3 weeks to give your tendons time to adapt.
2. Heart problems – theoretically possible.
Myosostatin is expressed not only in skeletal muscle but also in cardiac muscle. Although no cardiac pathological changes have been observed in primate studies, the long-term, systemic effects of myosostatin inhibition on the heart are not truly known. This is a big question mark.
3. Cancer Risk – A Theoretical Concern That Cannot Be Ignored
Follistatin works by inhibiting members of the TGF-β family, which plays a complex role in cancer regulation (both inhibiting early-stage tumors and promoting late-stage tumor invasion). More directly, the follistatin 288 isoform is associated with tumor and cancer cell development. While FS-344 primarily targets muscle, anything that promotes cell proliferation is absolutely forbidden for individuals with a history of cancer or active tumors.
4. No FDA Approval, No Safety Data for Subcutaneous Injection in Humans
Follistatin 344 has absolutely no FDA approval for any human indication. All human data comes from gene therapy trials, where the administration method, pharmacokinetics, and dose-response relationships are completely different from subcutaneous injection. Community dosing regimens you see are essentially based on educated guesswork, not clinical validation.
5. WADA Banned Drug
Attention competitive athletes: Myosin inhibitors are on the WADA banned drug list; their use is a violation.
6. A Special Version of Gene Therapy – Don't Get Confused
A product called MiniCircle Follistatin gene therapy has recently appeared on the market. It uses subcutaneous injection of plasmid DNA to temporarily express follistatin in cells for about one year. This is a completely different technical approach from traditional subcutaneous peptide injections, with different durations of effect and risk profiles. In clinical trials, participants gained an average of 2 pounds of muscle, lost 0.87% of their body fat, and experienced an average reduction in epigenetic age of 12 years. However, this falls under the category of gene therapy, and its risks and regulatory status are entirely different from traditional peptides.
Hot Tags: chinese research-specific peptide follistatin 344 1mg/vial, China chinese research-specific peptide follistatin 344 1mg/vial manufacturers, suppliers, factory
